These results were supported by clinical objective tumor responses; for example, in PATO020 containing a α-SMA/CK-19 ratio of more than 1.0, radiographic reductions in tumor size on computed tomography imaging during neoadjuvant treatment occurred after 5 cycles of FFX (3.5 × 2.8 cm to 1.4 × 2.3 cm, 74.2% tumor volume reduction; Figure 7D). The gene discussed is ACTA1; the disease is neoplasm.